Accretion Pharmaceuticals Limited Financial Ratios
ACCPL · Healthcare · Current price ₹193.2
P/E ratio
21.4x
P/B ratio
4.3x
ROE
17.7%
ROCE
20.8%
Debt / Equity
0.23
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 21.4x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 4.3x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 17.7% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 20.8% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.23 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Accretion Pharmaceuticals Limited's latest numbers.
Accretion Pharmaceuticals Limited profitability
Accretion Pharmaceuticals Limited generates a return on equity of 17.7% and a return on capital employed of 20.8%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.23 and a P/E of 21.4x, Accretion Pharmaceuticals Limited is conservatively financed. Our overall business-quality score for the company is 6.1 / 10.
Understand the ratios
More on Accretion Pharmaceuticals Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.